RXi Pharmaceuticals Corp. (RXII)

0.43
0.01 1.83
NASDAQ : Health Technology
Prev Close 0.44
Open 0.44
Day Low/High 0.43 / 0.46
52 Wk Low/High 0.27 / 2.56
Volume 221.92K
Avg Volume 1.26M
Exchange NASDAQ
Shares Outstanding 18.16M
Market Cap 6.00M
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

My biggest concern about the market continues to be a paucity of perky picks.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Stocks with insider trader activity include RXII, MA and SWN

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

Trade-Ideas LLC identified RXi Pharmaceuticals (RXII) as a strong on high relative volume candidate

The Trend Is Up

The Trend Is Up

If you turn bearish now, you'll quickly find yourself in trouble.

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase™ 2013

RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase™ 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At Biotech Showcase™ 2013

RXi Pharmaceuticals To Present At Biotech Showcase™ 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109

RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109

RXi Pharmaceuticals Corporation (OTC: RXII), today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated.

RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers

RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012

RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium

RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology

RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 11th Annual BIO Investor Forum

RXi Pharmaceuticals To Present At 11th Annual BIO Investor Forum

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Completion Of Dosing In Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Announces Completion Of Dosing In Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2012

RXi Pharmaceuticals Reports Financial Results For The Second Quarter Of 2012

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy...

RXi Pharmaceuticals Appoints Jeannette Graf MD And Leroy Young MD To Its Scientific Advisory Board

RXi Pharmaceuticals Appoints Jeannette Graf MD And Leroy Young MD To Its Scientific Advisory Board

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced the appointment of Dr.

RXi Pharmaceuticals Announces Initiation Of First Clinical Trial

RXi Pharmaceuticals Announces Initiation Of First Clinical Trial

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors

RXi Pharmaceuticals Appoints Robert Bitterman And Keith Brownlie To Board Of Directors

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that Robert Bitterman and Keith Brownlie have been appointed to the Company’s Board of Directors.

RXi Pharmaceuticals Receives FDA Clearance To Begin Clinical Trial With RXI-109

RXi Pharmaceuticals Receives FDA Clearance To Begin Clinical Trial With RXI-109

RXi Pharmaceuticals Corporation (OTCBB: RXII.OB) today announced that it has received clearance for its investigational new drug application (IND) from the U.